AstraZeneka resumes trials of COVID-19 vaccine
Pharmaceutical company AstraZeneka has resumed trials of its COVID-19 vaccine in the UK. This was reported on its official website.
The UK's Medicines Health Regulatory Authority (MHRA) has ruled further testing of AZD1222 vaccine is safe.
Trials of the development of AstraZeneca and the University of Oxford were stopped on September 6 worldwide after one of the subjects became seriously ill. Neither the developers nor the MHRA have disclosed what the man's health problems were. We only know that it was a dangerous and unexpected side reaction, which probably could not be associated with the vaccine.
As RIA Novosti has already stated in the Russian Direct Investment Fund (RDIF), the situation with the development of AstraZeneca has shown that a number of countries mistakenly focus exclusively on new, untested technologies when creating a vaccine.
In July, it was reported that the Russian “R-Pharm”, in agreement with AstraZeneca, will produce the Oxford vaccine against coronavirus in Russia.
A month ago, Russia announced the registration of the world's first vaccine against coronavirus. The production of Sputnik V was launched on 15 August. A number of government officials have already been vaccinated. In addition, President Vladimir Putin announced the appearance of the second vaccine variant from the Vector Center in September.